Retatrutide, a novel dual-action glucose-dependent insulinotropic polypeptide receptor agonist developed by Alluvi Healthcare, is sparking considerable anticipation within the medical community as a promising advancement in weight loss. Initial research data suggest a significant influence on body mass, often exceeding current existing therapies. T